Abstract
This study was aimed at resolving the time course of clinical action of antidepressants (ADs) and the type of early behavioral changes that precede recovery in treatment-responsive depressed patients. The first goal was to identify, during the first 2 weeks of treatment, the onset of clinical actions of the selective serotonin reuptake inhibitor (SSRI), paroxetine, and the selective noradrenergic reuptake inhibitor, desipramine (DMI). The second aim was to test the hypothesis that the two pharmacologic subtypes would induce different early behavioral changes in treatment-responsive patients. The design was a randomized, parallel group, placebo-controlled, double-blind study for 6 weeks of treatment following a 1-week washout period. The study utilized measures of the major behavioral components of the depressive disorder as well as overall severity. The results indicated that the onset of clinical actions of DMI ranged from 3 to 13 days, averaged 13 days for paroxetine, and was 16–42 days for placebo. Furthermore, as hypothesized, the different types of ADs initially impacted different behavioral aspects of the disorder. After 1 week of treatment, DMI produced greater reductions in motor retardation and depressed mood than did paroxetine and placebo, and this difference persisted at the second week of treatment. Early improvement in depressed mood–motor retardation differentiated patients who responded to DMI after 6 weeks of treatment from those that did not. Paroxetine initially reduced anxiety more in responders than in nonresponders, and by the second week, significantly improved depressed mood and distressed expression in responders to a greater extent. Depressed patients who responded to placebo showed no consistent early pattern of behavior improvement. Early drug-specific behavioral changes were highly predictive of ultimate clinical response to the different ADs, results that could eventually be applied directly to clinical practice.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Angst J (1970). Mechanism of action of imipramine and its therapeutics use. Tofranil J Angst Bern Stampfli Cie, BERN, p36.
Artigas F, Romero L, de Montigny C, Blier P (1996). Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 19: 378–383.
Aston-Jones G, Akaoka H, Charlety P, Chouvet G (1991). Serotonin selectively attenuates glutamate-evoked activation of noradrenergic locus coeruleus neurons. J Neurosci 11: 760–769.
Berridge CW, Foote SL (1991). Effects of locus coeruleus activation on electroencephalographic activity in neocortex and hippocampus. J Neurosci 11: 3135–3145.
Bonhomme N, Esposito E (1998). Involvement of serotonin and dopamine in the mechanism of action of novel antidepressant drugs: a review. J Clin Psychopharmacol 18: 447–454.
Bourin M, Chue P, Guillon Y (2001). Paroxetine: a review. CNS Drug Rev 7: 25–47.
Boyer WF, Feighner JP (1994). Clinical significance of early non-response in depressed patients. Depression 2: 32–35.
Briley M, Chopin P (1991). Serotonin in anxiety: evidence from animal models. In: Sandler M, Coppen A, Hartnett S (eds) 5-Hydroxytryptamine in Psychiatry. Oxford University Press: Oxford.
Buss AH, Durkee A (1957). An inventory for assessing different kinds of hostility. J Consult Psychology 21: 343–347.
Carlsson A, Corrodi H, Fuxe K, Hokfelt T (1969). Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-a-ethyl-meta-tyramine. Eur J Pharmacol 5: 357–366.
Chaouloff F, Berton O, Mormède P (1999). Serotonin and stress. Neuropsychopharmacol 21: 28S–32S.
Coccaro EF, Siever LJ, Klar HM, Maurer G, Cochrane K, Cooper TB et al (1989). Serotonergic studies in patients with affective and personality disorders. Correlates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry 46: 587–599.
Cohen J (1969). Statistical Power Analysis for the Behavioral Sciences. Academic Press: New York.
Coryell W, Coppen A, Zeigler VE, Biggs JT (1982). Early improvement as a predictor of response to amitriptyline and nortriptyline: a comparison of two patient samples. Psychol Med 12: 135–139.
Delgado PL, Moreno FA (2000). Role of norepinephrine in depression. J Clin Psychiatry 61(Suppl 1): 5–12.
Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L (1974). The Hopkins Symptom Checklist (HSCL): a measure of primary symptom dimensions. In: Psychological Measurements in Psychopharmacology: Modern Problems in Pharmacopsychiatry. Karger: Basel, 7: 79–110.
Dunbar GC, Fuell DL (1992). The anti-anxiety and anti-agitation effects of paroxetine in depressed patients. Int Clin Psychopharmacol 6: 81–90.
Endicott J, Spitzer R (1978). A diagnostic interview. The schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 34: 837–844.
Endicott J, Spitzer RL, Fleiss JL, Cohen J (1976). The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 33: 766–771.
Frazer A (1997). Antidepressants. J Clin Psychiatry 58(Suppl 6): 9–25.
Frazer A (2000). Norepinephrine involvement in antidepressant action. J Clin Psychiatry 61(Suppl 10): 25–30.
Gelenberg AJ, Chesen CL (2000). How fast are antidepressants? J Clin Psychiatry 61: 712–721.
Gorman JM (2002). Treatment of generalized anxiety disorder. J Clin Psychiatry 63: 17–23.
Guy W (1976). Early clinical drug evaluation program (ECDEU). In: Assessment Manual of Psychopharmacology. Department of Health, Education and Welfare: Rockville MD.
Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56–62.
Handley SL (1995). 5-Hydroxytryptamine pathways in anxiety and its treatment. Pharmacol Ther 66: 103–148.
Hosmer DW, Lemeshow S (1989). Applied Logistic Regression. Wiley: New York.
Jacobs BL, Abercrombie ED, Fornal CA, Levine ES, Morilak DA, Stafford IL (1991). Single-unit and physiological analyses of brain norepinephrine function in behaving animals. Prog Brain Res 88: 159–165.
Javors MA, Houston JP, Tekell JL, Brannan SK, Frazer A (2000). Reduction of platelet serotonin content in depressed patients treated with either paroxetine or desipramine. Int J Neuropsychopharmacol 3: 229–235.
Joyce PR, Paykel ES (1989). Predictors of drug response in depression. Arch Gen Psychiatry 46: 89–99.
Joyce PR, Mulder RT, Luty SE, McKenzie JM, Rae AM (2003). A differential response to nortriptyline and fluoxetine in melancholic depression: the importance of age and gender. Acta Psychiatr Scand 108: 20–23.
Katz MM, Itil TM (1974). Video methodology for research in psychopathology and psychopharmacology. Arch Gen Psychiatry 31: 204–210.
Katz MM, Koslow SH, Berman N, Secunda S, Maas JW, Casper R et al (1984). A multi-vantaged approach to measurement of behavioral and affect states for clinical and psychobiological research. Psychol Rep 55: 619–671.
Katz MM, Koslow SH, Frazer A (1996/1997). Onset of antidepressant activity: reexamining the structure of depression and multiple actions of drugs. Depression Anxiety 4: 257–267.
Katz MM, Koslow SH, Maas JW, Frazer A, Bowden CL, Casper R et al (1987). The timing, specificity and clinical prediction of tricyclic drug effects in depression. Psychol Med 17: 297–309.
Katz MM, Maas JW (1994). Psychopharmacology and the etiology of psychopathological states: are we looking in the right way? Neuropsychopharmacology 10: 139–144.
Katz MM, Maas JW, Frazer A, Koslow SH, Bowden CL, Berman N et al (1994). Drug-induced actions on brain neurotransmitter systems and changes in the behaviors and emotions of depressed patients. Neuropsychopharmacology 11: 89–100.
Katz MM, Robins E, Croughan J, Secunda A, Swann A (1982). Behavioral measurement and drug response characteristics of unipolar and bipolar depression. Psychol Med 17: 297–309.
Katz MM, Wetzler S, Koslow SH, Secunda S (1989). Video methodology in the study of the psychopathology and treatment of depression. Psychiatr Ann 19: 372–381.
Khan A, Cohen S, Dager S, Avery DH, Dunner DL (1989). Onset of response in relation to outcome in depressed outpatients with placebo and imipramine. J Affect Disord 17: 33–38.
Kieholz P, Poldinger W (1968). Die behandlung endogener depressionen mit psychopharmaka. Dt med Wschr 93: 701–704.
Kiloh LG, Andrews G, Neilson M (1988). The long-term outcome of depressive illness. Br J Psychiatry 153: 752–757.
Kirby LG, Allen AR, Lucki I (1995). Regional differences in the effects of forced swimming on extracellular levels of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid. Brain Res 682: 189–196.
Kirby LG, Chou-Green JM, Davis K, Lucki I (1997). The effects of different stressors on extracellular 5-hydroxytryptamine and 5-hydroxyindoleacetic acid. Brain Res 760: 218–230.
Kornstein SG, Schatzberg AF, Thase ME, Yonkers KA, McCullough JP, Keitner GI et al (2000). Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 157: 1445–1452.
Kuhn R (1958). The treatment of depressive states with G 22355 (imipramine hydrochloride). Am J Psychiatry 115: 459–464.
Laird NM, Ware JH (1982). Random effects model for longitudinal data. Biometrics 38: 963–974.
Linnoila M, Virkkunen M, Scheinin M, Nuutila A, Rimon R, Goodwin FK (1983). Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior. Life Sci 33: 2609–2614.
Lydiard RB, Bobes J (2000). Therapeutic advances: paroxetine for the treatment of social anxiety disorder. Depress Anxiety 11: 99–104.
Montgomery SA (1992). The advantages of paroxetine in different subgroups of depression. Int Clin Psychopharmacol 6: 91–110.
Murphy DL, Pickar D, Alterman JS (1980). Methods for the quantitative assessment of depressive and manic behavior. In: Burdock EJ, Sudilovsky A, Gershon S (eds) Quantitative Techniques for the Evaluation of the Behavior of Psychiatric Patients. Marcel-Decker: New York, 355–392.
Nagayama H, Nagano H, Ikezaki A, Tashiro T (1991). Prediction of efficacy by 1-week test therapy in depression. J Affect Disord 23: 213–216.
Page ME, Berridge CW, Foote SL, Valentino RJ (1993). Corticotropin-releasing factor in the locus coeruleus mediates EEG activation associated with hypotensive stress. Neurosci Lett 164: 81–84.
Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew KM, Burnham DB et al (2001). Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 62: 350–357.
Quitkin FM, Rabkin JD, Markowitz JM, Stewart JW, McGrath PJ, Harrison W (1987). Use of pattern analysis to identify true drug response: a replication. Arch Gen Psychiatry 44: 259–264.
Quitkin FM, Rabkin JG, Ross D, Stewart JW (1984). Identification of true drug response to antidepressants. Arch Gen Psychiatry 41: 782–786.
Raskin A, Schulterbrandt J, Reatig N, McKeon JJ (1969). Replication of factors of psychopathology in interview, ward behavior, and self-ratings of hospitalized depressives. J Nerv Ment Dis 148: 87–98.
Rasmussen K, Morilak DA, Jacobs BL (1986). Single unit activity of locus coeruleus neurons in the freely moving cat. I. During naturalistic behaviors and in response to simple and complex stimuli. Brain Res 371: 324–334.
Rosario LA, Abercrombie ED (1999). Individual differences in behavioral reactivity: correlation with stress-induced norepinephrine efflux in the hippocampus of Sprague–Dawley rats. Brain Res Bull 48: 595–602.
Rueter LE, Jacobs BL (1996). A microdialysis examination of serotonin release in the rat forebrain induced by behavioral/environmental manipulations. Brain Res 739: 57–69.
Small JG, Milstein V, Kellams JF, Small IF (1981). Comparative onset on improvement in depressive symptomatology with drug treatment electroconvulsive therapy, and placebo. J Clin Psychopharmacol 1(Suppl 6): 62S–69S.
Soubrié P (1986). Reconciling the role of central serotonin neurons in human and animal behavior. Behav Brain Sci 9: 319–363.
Spitzer RL, Williams JBW (1983). Instruction manual For the Structured Clinical Interview for DSM III (SCID), Revision. Biometrics Research Department, M.Y. State Psychiatric Institute: New York.
Spoont MR (1992). Modulatory role of serotonin in neural information processing: implications for human psychopathology. Psychol Bull 112: 330–350.
Stassen HH, Angst J, Delini-Stula A (1997). Delayed onset of action of antidepressant drugs? Survey of recent results. Eur Psychiatry 12: 166–176.
Stassen HH, Delini-Stula A, Angst J (1993). Time course of improvement under antidepressant treatment: a survival-analytical approach. Eur Neuropsychopharmacol 3: 127–135.
Szegedi A, Muller MJ, Anghelescu I, Klawe C, Kohnen R, Benkert O (2003). Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry 64: 413–420.
Tollefson GD, Holman SL (1994). How long to onset of antidepressant action: a meta-analysis of patients treated with fluoxetine or placebo. Int Clin Psychopharmacol 9: 245–250.
Willner P (1997). Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacol 134: 319–329.
Acknowledgements
We thank Virginia Haigler and Valerie Dullnig for monitoring and coordinating all aspects of the study in San Antonio and Greer Garner, PhD, Janice Melester, PhD, and Evelyn Gaspard-Parker, PhD for doing the same at the study site in Dallas. Virginia Doyle, Pharm D, provided excellent assistance with the study medications and Cynthia Foslein-Nash, Pharm D provided coordination with the Dallas Research Pharmacy. We thank Dr Marty Javors, Department of Psychiatry at the UTHSCSA, for supervising the assays for concentrations of the drugs in serum and also acknowledge Paul A Orsulak, PhD, Frederick Petty, PhD, MD, and Gerald Kramer for research lab support in Dallas.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Katz, M., Tekell, J., Bowden, C. et al. Onset and Early Behavioral Effects of Pharmacologically Different Antidepressants and Placebo in Depression. Neuropsychopharmacol 29, 566–579 (2004). https://doi.org/10.1038/sj.npp.1300341
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1300341
Keywords
This article is cited by
-
The why, when, where, how, and so what of so-called rapidly acting antidepressants
Neuropsychopharmacology (2024)
-
Optimizing prediction of response to antidepressant medications using machine learning and integrated genetic, clinical, and demographic data
Translational Psychiatry (2021)
-
Behavioral and dopamine transporter binding properties of the modafinil analog (S, S)-CE-158: reversal of the motivational effects of tetrabenazine and enhancement of progressive ratio responding
Psychopharmacology (2020)
-
Variance of the global signal as a pretreatment predictor of antidepressant treatment response in drug-naïve major depressive disorder
Brain Imaging and Behavior (2018)
-
Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis
BMC Psychiatry (2017)
